Search results for Camidanlumab ELISA Kit
Camidanlumab ELISA Kit, ProteoGenix, KPTX134
Description of Camidanlumab ELISA Kit Introduction to Camidanlumab ELISA Kit Camidanlumab ELISA Kit is a highly sensitive and specific tool used for the detection and quantification of Camidanlumab, a novel therapeutic antibody. This kit is designed for researchers and clinicians who are interested in studying the structure, activity, and application of Camidanlumab in various disease conditions. In this article, we will provide a detailed description of the Camidanlumab ELISA Kit, its components, and its potential applications. Structure of Camidanlumab Camidanlumab, also known as MEDI9197, is a fully human monoclonal antibody that specifically targets the stimulator of interferon genes (STING) protein. STING is a key mediator of the innate immune response and plays a crucial role in the activation of type I interferon pathway. Camidanlumab is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. It has a unique structure that allows it to bind to STING and modulate the immune response in a highly specific manner. Activity of Camidanlumab The main activity of Camidanlumab is its ability to activate the STING pathway and induce the production of type I interferons. This leads to the activation of various immune cells, such as dendritic cells, natural killer cells, and T cells, which play a crucial role in the elimination of infected or cancerous cells. Camidanlumab has also been shown to enhance the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which further contribute to the anti-tumor or anti-viral activity of this antibody. Application of Camidanlumab ELISA Kit The Camidanlumab ELISA Kit has a wide range of applications in both research and clinical settings. Some of the key applications of this kit include: 1. Detection and quantification of Camidanlumab The Camidanlumab ELISA Kit is specifically designed to detect and quantify Camidanlumab in various biological samples, such as serum, plasma, and cell culture supernatants. This allows researchers to monitor the levels of Camidanlumab in response to treatment or disease progression. The high sensitivity and specificity of this kit make it a valuable tool for pharmacokinetic studies and biomarker analysis. 2. Screening of STING pathway activity Since Camidanlumab targets the STING protein, this ELISA Kit can also be used to assess the activity of the STING pathway in various disease conditions. By measuring the levels of type I interferons and pro-inflammatory cytokines, researchers can determine the extent of STING pathway activation and its potential role in disease progression. 3. Evaluation of Camidanlumab efficacy In pre-clinical and clinical studies, the Camidanlumab ELISA Kit can be used to evaluate the efficacy of this antibody in different disease models. By measuring the levels of Camidanlumab and its downstream effects, researchers can assess the potency of this antibody and its potential for therapeutic use. 4. Monitoring of Camidanlumab treatment response In patients receiving Camidanlumab therapy, the ELISA Kit can be used to monitor the levels of this antibody and its impact on the immune response. This can help clinicians to adjust the dosage or treatment schedule for optimal efficacy. 5. Identification of potential biomarkers Lastly, the Camidanlumab ELISA Kit can also be used to identify potential biomarkers for various diseases. By measuring the levels of Camidanlumab and its downstream effects, researchers can identify specific immune
Host
Reactivity
Applications
Conjugation
Camidanlumab ELISA Kit, Abbexa, abx395023
Camidanlumab ELISA Kit is a quantitative ELISA kit for detection of Camidanlumab.Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory ALL/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3-92 μg/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (>10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamyltransferase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. Two patients achieved complete responses with incomplete hematologic recovery; one each at 30 and 37.5 μg/kg QW. The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.